drugset
drugset / Trial / NCT05648799

Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia)

NCT05648799 ↗

Completed 246 enrolled Geropharm
RandomizedParallel-groupOpen-labelTreatment

Summary

Pharmacokinetics, safety and efficacy study of GP30341, 200 mg capsules (GEROPHARM LLC, Russia) in healthy volunteers and patients with novel coronavirus infection 2019 (COVID-19) with a high risk of adverse outcome

Timeline

Start
2022-03-17
Primary completion
2022-05-11
Completion
2022-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject GP30341 Unknown 800 mg Oral

Indications

No indication recorded.